We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation (CASTLE-HTx)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04649801
Recruitment Status : Recruiting
First Posted : December 2, 2020
Last Update Posted : September 20, 2021
Information provided by (Responsible Party):
Heart and Diabetes Center North-Rhine Westfalia

Brief Summary:
CASTLE-HTx will determine if AF ablation has beneficial effects on mortality in patients with end stage HF who are eligible for HTx

Condition or disease Intervention/treatment Phase
Heart Failure Atrial Fibrillation Procedure: Atrial fibrillation ablation Not Applicable

Detailed Description:
CASTLE-HTx is a randomized evaluation of ablative treatment of AF in patients with severe left ventricular dysfunction who are candidates and eligible for HTx. The primary endpoint is the composite of all-cause mortality, worsening of HF requiring a high urgent transplantation or LVAD implantation. The secondary study endpoints are all-cause mortality, cardiovascular mortality, cerebrovascular accidents, worsening of HF requiring unplanned hospitalization, AF burden reduction, unplanned hospitalization due to cardiovascular reason, all-cause hospitalization, QoL, number of delivered implantable cardioverter-defibrillator (ICD) therapies, time to first ICD therapy, number of device-detected ventricular tachycardia/ventricular fibrillation episodes, LV function, exercise tolerance, and percentage of right ventricular pacing. Ventricular myocardial tissue will be obtained from patients who will undergo LVAD implantation or HTx to assess the effect of catheter ablation on human HF myocardium.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 194 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation (CASTLE-HTx)
Actual Study Start Date : December 1, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: conventional
Active Comparator: interventional Procedure: Atrial fibrillation ablation
Catheter ablation

Primary Outcome Measures :
  1. Mortality or transplantation [ Time Frame: 24 months ]
    composite of all-cause mortality, worsening of HF requiring a high urgent transplantation or implantation of a ventricular assist device

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Symptomatic paroxysmal or persistent AF (paroxysmal: ≥2 symptomatic or one documented AF episode lasting 30 seconds or more in the last 3 months; persistent: ≥1 documented episode in the last 3 months).
  2. Eligible for heart transplantation due to end-stage heart failure
  3. LV dysfunction with left ventricular ejection fraction ≤ 35% (measured in the last 6 weeks prior to enrollment).
  4. NYHA class ≥ II.
  5. Indication for ICD therapy due to primary prevention.
  6. Dual chamber ICD with Home Monitoring capabilities already implanted.
  7. The patient is willing and able to comply with the protocol and has provided written informed consent.
  8. Sufficient GPRS-network coverage in the patient's area.
  9. Age ≥ 18 years.

Exclusion Criteria:

  1. Documented left atrial diameter > 6 cm (parasternal long-axis view)
  2. Contraindication for chronic anticoagulation therapy or heparin
  3. Previous left heart ablation procedure for atrial fibrillation
  4. Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 2 months prior to enrollment
  5. Untreated hypothyroidism or hyperthyroidism
  6. Enrollment in another investigational drug or device study
  7. Indication for cardiac resynchronization therapy
  8. Woman currently pregnant, breastfeeding, or not using reliable contraceptive measures during fertility age
  9. Mental or physical inability to participate in the study
  10. Listed as "high urgent" for heart transplantation
  11. Cardiac assist device implanted
  12. Planned cardiovascular intervention
  13. Life expectancy ≤ 12 month
  14. Uncontrolled hypertension
  15. Requirement for dialysis due to end-stage renal failure
  16. Participation in another telemonitoring concept

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04649801

Layout table for location contacts
Contact: Christian Sohns, MD 49 5731 971327 csohns@hdz-nrw.de
Contact: Astrid Kleemeyer 49 5731 971258 akleemeyer@hdz-nrw.de

Layout table for location information
Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum Recruiting
Bad Oeynhausen, Germany, 32545
Contact: Astrid R Kleemeyer    +49495731971258    akleemeyer@hdz-nrw.de   
Principal Investigator: Christian Sohns, MD         
Sponsors and Collaborators
Heart and Diabetes Center North-Rhine Westfalia
Layout table for additonal information
Responsible Party: Heart and Diabetes Center North-Rhine Westfalia
ClinicalTrials.gov Identifier: NCT04649801    
Other Study ID Numbers: HDZ_ER002_CS
First Posted: December 2, 2020    Key Record Dates
Last Update Posted: September 20, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Atrial Fibrillation
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes